hypertensive crisis mohammed r arafah mbbs facp frcpc facc professor of cardiology
TRANSCRIPT
HYPERTENSIVE CRISIS
MOHAMMED R ARAFAHMBBS FACP FRCPC FACC
PROFESSOR OF CARDIOLOGY
Proposed new definition of hypertension
is a progressive cardiovascular syndrome arising from complex and interrelated etiologies.
Early markers of the syndrome are often present before blood-pressure elevation is sustained; therefore, hypertension cannot be classified solely by discreet blood-pressure thresholds.
Progression is strongly associated with function and structural cardiac and vascular abnormalities that damage the heart, kidneys, brain, vasculature and other organs and lead to premature morbidity and death.
ASH Writing Group 2005
Blood Pressure Classification
Normal <120 and <80
Prehypertension 120–139 or 80–89
Stage 1 Hypertension 140–159 or 90–99Stage 2 Hypertension >160 or >100
BP Classification SBP mmHg DBP mmHg
Joint National Committee VII
Hypertensive Urgencies and Emergencies
Patients with marked BP elevations and acute TOD (e.g., encephalopathy, myocardial infarction, unstable angina, pulmonary edema, eclampsia, stroke, head trauma, life-threatening arterial bleeding, or aortic dissection) require hospitalization and parenteral drug therapy.
Patients with markedly elevated BP but without acute TOD usually do not require hospitalization, but should receive immediate combination oral antihypertensive therapy.
Joint National Committee VII
GFRProteinuriaAldosterone releaseGlomerular sclerosis
Target Organ DamageTarget Organ Damage
Adapted from Willenheimer R et al Eur Heart J 1999; 20(14): 9971008, Dahlöf B J Hum Hypertens 1995; 9(suppl 5): S37S44, Daugherty A et al J Clin Invest 2000; 105(11): 16051612, Fyhrquist F et al J Hum Hypertens 1995; 9(suppl 5): S19S24, Booz GW, Baker KM Heart Fail Rev 1998; 3: 125130, Beers MH, Berkow R, eds. The Merck Manual of Diagnosis and Therapy. 17th ed. Whitehouse Station, NJ: Merck Research Laboratories 1999: 16821704, Anderson S Exp Nephrol 1996; 4(suppl 1): 3440, Fogo AB Am J Kidney Dis 2000; 35(2): 179188
Atherosclerosis*VasoconstrictionVascular hypertrophyEndothelial dysfunction
LV hypertrophyFibrosisRemodelingApoptosis
Stroke
DEATH
*preclinical dataLV = left ventricular; MI = myocardial infarction; GFR = glomerular filtration rate
Hypertension
Heart failureMI
Renal failure
Target Organ DamageTarget Organ Damage
Heart• Left ventricular hypertrophy• Angina or prior myocardial infarction• Prior coronary revascularization• Heart failure
Brain• Stroke or transient ischemic attack
Chronic kidney disease
Peripheral arterial disease Retinopathy
Joint National Committee VII
SystolicSystolicdysfunctiodysfunctio
nn
DiastolicDiastolicdysfunctiodysfunctio
nn
HypertensionHypertension
LVHLVH
MIMI
CHCHFF
LV remodellingLV remodellingNormal LV structureNormal LV structureand functionand function
Subclinical LVSubclinical LVddysfunctionysfunction
Overt heartOvert heartfailurefailure
ObesityObesityDiabetesDiabetes
SmokingSmokingDyslipidemiaDyslipidemia
DiabetesDiabetes
Vasan RS et al. Arch Intern Med 1996Vasan RS et al. Arch Intern Med 1996
Progression From Hypertension to CHFProgression From Hypertension to CHF
Increasing Systolic BP Linked to End-Increasing Systolic BP Linked to End-Stage Renal Disease Risk: MRFITStage Renal Disease Risk: MRFIT
1 11.5
2.2
5
0
1
2
3
4
5
6
<117 117-123 124-130 131-140 >140
Klag et al. Klag et al. N Engl J MedN Engl J Med. 1996;334:13-18.. 1996;334:13-18.
PP=.009=.009PP<.001<.001
PP<.001<.001
Ad
just
ed
Re
lati
ve R
isk
Systolic BP (mm Hg)
MANAGMENTMANAGMENT
In hypertensive urgencies critically In hypertensive urgencies critically elevated BP should be lowered rapidly elevated BP should be lowered rapidly (within 15(within 15--30minutes reduction of MBP 30minutes reduction of MBP by 25%, aim DBP 100-110, SBP 160 mm by 25%, aim DBP 100-110, SBP 160 mm Hg) .Hg) .
Avoid sudden drop of BP which lead to Avoid sudden drop of BP which lead to reduction of perfusion to vital organs reduction of perfusion to vital organs (brain, heart,. etc).(brain, heart,. etc).
In hypertensive emergencies critically elevated In hypertensive emergencies critically elevated BP should be lowered gradually within hours BP should be lowered gradually within hours (aim DBP 100-110 mm Hg, SBP 160 mm Hg).(aim DBP 100-110 mm Hg, SBP 160 mm Hg).
Benefits of Lowering BPBenefits of Lowering BP
Average Percent Reduction
Stroke incidence 35–40%
Myocardial infarction 20–25%
Heart failure 50%
Joint National Committee VII
Patient EvaluationPatient Evaluation
Evaluation of patients with documented HTN has three objectives:
1. Assess lifestyle and identify other CV risk factors or concomitant disorders that affects prognosis and guides treatment.
2. Reveal identifiable causes of high BP.
3. Assess the presence or absence of target organ damage and CVD.
Joint National Committee VII
CVD Risk FactorsCVD Risk Factors
Hypertension* Cigarette smoking Obesity* (BMI >30 kg/m2) Physical inactivity Dyslipidemia* Diabetes mellitus* Microalbuminuria or estimated GFR <60 ml/min Age (older than 55 for men, 65 for women) Family history of premature CVD
(men under age 55 or women under age 65)*Components of the metabolic syndrome.
Joint National Committee VII
Identifiable Causes of HypertensionIdentifiable Causes of Hypertension
Sleep apnea Drug-induced or related causes Chronic kidney disease Primary aldosteronism Renovascular disease Chronic steroid therapy and Cushing’s syndrome Pheochromocytoma Coarctation of the aorta Thyroid or parathyroid disease
Joint National Committee VII
Laboratory TestsLaboratory Tests
Routine Tests• Electrocardiogram • Urinalysis • Blood glucose, and hematocrit • Serum potassium, creatinine, or the corresponding estimated GFR,
and calcium• Lipid profile, after 9- to 12-hour fast, that includes high-density and
low-density lipoprotein cholesterol, and triglycerides
Optional tests • Measurement of urinary albumin excretion or albumin/creatinine ratio
More extensive testing for identifiable causes is not generally indicated unless BP control is not achieved
Joint National Committee VII
Goals of TherapyGoals of Therapy
Reduce CVD and renal morbidity and mortality.
Treat to BP <140/90 mmHg or BP <130/80 mmHg in patients with diabetes or chronic kidney disease.
Achieve SBP goal especially in persons >50 years of age.
Joint National Committee VII
Causes of Resistant Hypertension
Improper BP measurement Excess sodium intake Inadequate diuretic therapy Medication
• Inadequate doses• Drug actions and interactions (e.g., nonsteroidal anti-inflammatory
drugs (NSAIDs), illicit drugs, sympathomimetics, oral contraceptives)• Over-the-counter (OTC) drugs and herbal supplements
Identifiable causes of HTN
Joint National Committee VII
Achieved DBPmm Hg
Risk of a major cardiovascular event reducedRisk of a major cardiovascular event reducedby 30% in the HOT Studyby 30% in the HOT Study
0
5
10
15
20
25
30
105 100 95 90 85 80
% risk reduction
Optimal DBPreduction in theHOT Study
Achieved SBPmm Hg
Risk of a major cardiovascular event reducedRisk of a major cardiovascular event reducedby 22% in the HOT Studyby 22% in the HOT Study
0
5
10
15
20
25
30
170 160 150 140 130
% risk reduction
Optimal SBPreduction in theHOT Study